Biotech Values

[tony111]

If you believe in the limited distribution of IL-29r and the phase 1 preliminary data, I do think interferon lambda monotherapy will have less side effects than direct anti virals. Does it concern you that Zymo is enrolling another cohort at 0.5mg ? I do hope its a sign that interferon lambda is too potent so its difficult to access the minimum effective dose :)